Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
EASL Recommendations on Treatment of Hepatitis C 2015

These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, in the clinical decision-making process by describing the optimal management of patients with acute and chronic HCV infections.

Published
23 April 2015
From
EASL
Gilead uses Georgia as free-drug testbed for hepatitis C elimination

Gilead Sciences is seeking to convince governments and multilateral agencies worldwide that hepatitis C can be eliminated with a demonstration project in Georgia offering free drugs to all those who need them.

Published
23 April 2015
From
Reuters
Report: Hepatitis C in Eastern Europe and Central Asia: Epidemic and Response

The purpose of this report is to provide an overview of some of the key aspects of the hepatitis C (HCV) epidemic and response in Eastern Europe and Central Asia (EECA). It is also intended to outline tools and opportunities for civil society (CS) and community-based groups and individuals working on expanding access to HCV treatment in the region.

Published
23 April 2015
From
EATG
Many European countries ill-prepared to prevent and control the spread of viral hepatitis

Many countries in the World Health Organization European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015.

Published
23 April 2015
From
Eurekalert Medicine & Health
Union of South American Nations (UNASUR) proposes centralised purchase of hepatitis C treatments Olysio and Sovaldi for member states

Regional agency UNASUR is aiming to secure price discounts on Sovaldi (sofosbuvir; Gilead Sciences, US) and Olysio (simeprevir; Janssen-Cilag, US), generating savings and reducing the risk of compulsory licences or price cuts.

Published
21 April 2015
From
IHS
Is There Any Good Reason Left to Delay Hepatitis C Treatment?

Physicians increasingly argue that the best choice is to get rid of hepatitis C right away. But your insurance company may not agree. How risky is it to wait for treatment?

Published
17 April 2015
From
Poz
Cepheid announces European approval of Xpert HCV Viral Load

Quantitative test for rapid measurement of hepatitis C virus viral load and confirmation of HCV infection delivers on-demand results in less than 2 hours.

Published
16 April 2015
From
Cepheid press release
Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

Published
09 April 2015
From
The Street
Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations

Merck today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic HCV genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis.

Published
09 April 2015
From
Merck press release
At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

Published today in the journal Science Translational Medicine, researchers from the National Institutes of Health (NIH) reported chlorcyclizine prevented hepatitis C infection in a petri dish and in humanized mice. They said it was effective and did and did not produce any significant cell toxicity when given along with existing drugs to treat hepatitis C.

Published
09 April 2015
From
Healthline
← First12345...91Next →

Filter by country